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This study was performed to explore novel molecularly- targeted therapeutic options 
which could modulate antiapoptotic proteins in endometrial and ovarian carcinomas. 
The incidence of endometrial carcinoma is rising in most parts of the world, and 
mortality rates due to ovarian carcinoma are still unacceptably high. The study focused 
on “survivin”, an antiapoptotic protein and a member of IAP (inhibitor of apoptosis) 
family which is highly expressed in most of the human cancers, but almost completely 
undetectable in normal terminally differentiated cells. 
To investigate the role of survivin in apoptosis-based therapies for endometrial and 
ovarian carcinomas, the prognostic significance of the expression of a survivin gene-
BIRC5 was evaluated in endometrial carcinoma clinical samples. A panel of sixteen 
endometrial cancer cell lines and ten ovarian cancer cell lines derived from different 
histology were analyzed. Cells were either untreated or treated with a survivin 
suppressant- Y155 (sepantronium bromide), kaempferol (natural dietary flavonoid) or 
celecoxib (COX-2 inhibitor), and antitumor effect were analyzed. At some point, 
hormone-receptor positive Ishikawa and HEC-265 endometrial cancer cell lines were 
treated with estradiol before analysis to gain insight of its role in ERα (estrogen 
receptor-alpha)/ survivin signaling. 
 
In this study, the following results were observed;  
Higher expression levels of BIRC5 gene were associated with poor progression-free 
survival (PFS) (p= 0.006) and showed a strong tendency towards poor overall survival 
(OS) (p= 0.06) as evaluated by Kaplan-Meier survival analysis and a log-rank test. A 
multivariate analysis showed that high expression of BIRC5 gene is an independent 
poor prognostic factor in endometrial carcinoma (HR= 1.97, 95% CI = 1.29–4.5, p= 
0.045). Survivin protein was highly upregulated in over 87% of endometrial carcinoma 
cell lines. Survivin suppressant-YM155 successfully suppressed the growth of all 
analyzed endometrial carcinoma cell lines at IC50 values ranging from 14nM to 150nM. 
YM155 also induced significantly sub-G1 cell population (p< 0.001) and apoptotic cell 
death (p< 0.001). Further evaluation revealed that YM155 suppresses survivin, induces 
cleaved caspase-7 and cleaved PARP (poly (ADP-ribose) polymerase). Knockdown of 
BIRC5 gene by siRNAs caused similar effects. Kaempferol suppressed the growth 
Ishikawa and HEC-265 endometrial carcinoma cell lines at IC50 values of 83μM and 
65μM respectively. It also induced sub-G1 and G2/M cell populations in a cell cycle (p< 
0.05) and apoptosis (p<0.001). Estradiol induced nuclear co-expression of ERα and 
survivin, an effect which was inhibited by kaempferol. Kaempferol also suppressed 
survivin and Bcl-2, and induced p53 and induction of cleaved PARP. Celecoxib 
suppressed growth of ovarian carcinoma cells at IC50 values ranging from 17µM to 
45µM, induced sub-G1 (p< 0.01), suppressed the expression of survivin and 
significantly induced an apoptotic cell death in all ten analyzed cell lines (p< 0.01). 
 
In conclusion, this study has found for the very first time that high expression level of 
survivin gene-BIRC5 may be a potential biomarker for poor prognosis in endometrial 
carcinoma. It has also demonstrated novel antitumor mechanisms of kaempferol and 
celecoxib through suppression of survivin in endometrial and ovarian carcinomas 
respectively. Unlike other apoptosis-based therapies, survivin-targeting therapies may 
offer additional advantages by antagonizing multiple cellular signaling networks and 
providing more favorable toxicity profile since it does not affect normal cells or tissues.  
 
